Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Update

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) saw a large decrease in short interest in December. As of December 15th, there was short interest totalling 2,300 shares, a decrease of 88.7% from the November 30th total of 20,400 shares. Based on an average daily volume of 198,200 shares, the short-interest ratio is currently 0.0 days.

Chugai Pharmaceutical Trading Down 0.3 %

Shares of Chugai Pharmaceutical stock traded down $0.06 during mid-day trading on Thursday, hitting $21.95. 78,931 shares of the stock were exchanged, compared to its average volume of 127,127. The stock has a market capitalization of $72.24 billion, a price-to-earnings ratio of 28.14 and a beta of 0.82. Chugai Pharmaceutical has a twelve month low of $14.52 and a twelve month high of $26.00. The company has a 50-day simple moving average of $22.50 and a 200 day simple moving average of $21.74.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.